Biosurgery Market Analysis and Forecast to 2031: By Product (Bone Graft Substitutes, Soft-tissue Attachments, Hemostatic Agents, Surgical Sealant and Adhesives, Adhesion Barrier, Staple-Line Reinforcement Agents), Application (Orthopedic Surgery, General

Biosurgery Market Analysis and Forecast to 2031: By Product (Bone Graft Substitutes, Soft-tissue Attachments, Hemostatic Agents, Surgical Sealant and Adhesives, Adhesion Barrier, Staple-Line Reinforcement Agents), Application (Orthopedic Surgery, General Surgery, Neurological Surgery, Cardiovascular Surgery, Reconstructive Surgery, Gynecological Surgery, Urological Surgery, Thoracic Surgery, Others), End User (Hospitals, Clinics, Others), and Region

The global biosurgery market size was USD 12.4 Bn in 2021 and is anticipated to reach USD 21.2 Bn in 2031, growing at a rate of 5.5% from 2022 to 2031.

Biosurgery is a medical procedure that comprises the use of natural, synthetic, or semi-synthetic materials to seal surgical incisions and wounds. It is majorly used for preventing excessive blood loss, providing adhesion for wound and tissue sealing, and repairing damaged tissue and bones. Biosurgeries are usually conducted through the various hemostatic sealants, soft tissue repair, bone graft substitutes, adhesion prevention, and staple line reinforcement products. They also utilize natural allografts, cultured epithelial autografts, cultured epithelial autografts, and xenografts for minimizing intra and post-operative complications and promoting faster recovery of the patients.

Biosurgery Market Scope and Structure Analysis

Market Trends and Drivers

The major factors boosting the growth of the biosurgery market is the increasing volume of surgeries and the growing prevalence of severe trauma injuries. Adhesion formation is a major post-surgical complication, which results in healthcare complications and generally requires repeat surgeries for the treatment of affected patients. Post-surgical adhesion formation leads to different complications in different surgeries, like severe abdominal pain in the case of abdominal surgeries, infertility in women after gynaecological surgeries, and physical impairment of patients after neurological surgeries. Considering the severe effects of post-surgery adhesion formation in patients, the importance of products such as adhesion barriers is increasing in the market. Also, considering the growth in the number of surgeries performed globally, the importance of these products will be more prominent in the forthcoming years.

Likewise, the growing adoption of advanced biosurgery products in emerging markets is also boosting the growth of the biosurgery market. The penetration of biosurgery products is increasing across emerging countries, specifically based in the Asia Pacific, Latin America, and the Middle East and Africa. In the coming years, countries such as China, India, and Brazil are expected to offer significant growth opportunities for players operating in the biosurgery market. This is because the markets in these countries are characterized by a large patient base for target indications (like cardiovascular, orthopedic, general/abdominal, and gynecologic disorders), rising health awareness, growing healthcare expenditure, rising medical tourism, coupled with rapidly developing healthcare infrastructure. Over the last few decades, countries such as India and Malaysia have emerged as hubs for medical tourism. This is because the cost of medical procedures across these emerging countries is significantly less in comparison to developed countries such as the US, Germany, France, and the UK. Moreover, government agencies in several Asia Pacific and Middle East countries are undertaking initiatives to support their respective healthcare systems, which is providing lucrative growth opportunities to the biosurgery product manufacturers across emerging countries.

Market Restraints & Challenges

one of the primary challenges in the growth of the global biosurgery market is the high price of biosurgery products and the rising cost of surgical products. The biosurgery market is extremely competitive in terms of pricing, due to the highly competitive intensity among existing players. Most of the products available in this market are priced at a premium. The high cost, combined with the unfavourable reimbursement scenario for these products in emerging countries, makes them unaffordable for a large section of the target patient population. Owing to the high cost of biosurgery products, conventional procedures such as sutures and ligature-based procedures are preferred during surgeries across emerging countries. Adding to that, the biosurgery products currently available in the market are made of complicated reconstitutes with a poor shelf life. So, there is a growing need for low-priced products that are easy to handle and have a better shelf life.

Global Biosurgery Market Segmentation

The report analyses the biosurgery market based on product, application, end-user, and regions.

Global Biosurgery Market by Product

On the basis of product, it is segmented into bone graft substitutes, soft-tissue attachments, hemostatic agents, surgical sealants and adhesives, adhesion barriers, and staple-line reinforcement agents. The bone graft substitutes segment is likely to dominate the market during the forecast period. The key factors such as the increasing use of bone-graft substitutes across different types of orthopedic surgeries as they reduced surgical time are propelling the market growth of the segment. The bone substitutes can be broadly categorized into bone grafts (autografts, allografts, xenografts), ceramics and growth factors. The ideal bone substitutes should be biocompatible and not evoke any adverse inflammatory response.

Global Biosurgery Market by Application

Based on application, it is segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, reconstructive surgery, gynecological surgery, urological surgery, thoracic surgery, and others. The reconstructive surgery segment is anticipated to dominate the market during the forecast period. The key factors such as the increasing number of facial cosmetic surgeries combined with increasing cases of skin injuries, growing incidences of burn injuries, and an increasing number of breast cancer patients undergoing mastectomy and breast reconstruction procedures are the major factors driving the growth of this segment.

Global Biosurgery Market by End User

Based on the end-user, it is segmented into hospitals, clinics, and others. The hospital segment is likely to dominate the market during the forecast period. The key factors attributing to the growth of the market are the increasing number of surgeries taking place across the globe coupled with the rising geriatric population and the incidence of various diseases. Additionally, the increasing need to control blood loss and achieve efficient homeostasis and wound closure in trauma cases, injuries, or surgical procedures is leading to the increasing adoption of biosurgery products by surgeons.

Geographical Analysis of Global Biosurgery Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is anticipated to dominate the global biosurgery market over the forecast period. This is attributed to the significant number of prominent vendors, a highly developed healthcare system, an increasing number of surgeries, rising obese patients, and an increasing geriatric population. The Asia Pacific region is to grow at the highest CAGR over the forecast period. This can be attributed to the growing aging population, favorable government initiatives, rising per capita income, and increasing investments in the healthcare infrastructure. Europe is expected to hold the second-largest market share over the forecast period.

Major Players of the Global Biosurgery Market

The global biosurgery market report includes players such as Johnson & Johnson (US), Baxter International Inc. (US), Medtronic Plc (Ireland), Becton, Dickinson & Co. (US), B. Braun Melsungen AG (Germany), Stryker Corp. (US), Integra Lifesciences Holdings Corp. (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Cyrolife Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew Plc. (UK), Tissue Regenix Group Plc (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Biom'Up (France), BioCer Entwicklungs-GmbH (Germany), and Hannox International Corp. (Taiwan) among others.

COVID-19 Analysis

According to the International Monetary Fund (IMF), due to the epidemic of a novel coronavirus, the worldwide economy decreased by over 3.0% in 2020. Several nations were under strict lockdowns in 2020 & 2021, which have impacted the supply of raw materials. Therefore, due to this, the manufacturing activities of biosurgery producers have ceased. While some biosurgery is considered urgent, others have been postponed and delayed since the beginning of the global pandemic. The other aspect negatively affecting the market is the drop in the diagnosis of obesity owing to healthcare resources being reserved for COVID-19 patients. Owing to the growing incidence of COVID-19, hospitals became high-risk zones, specifically for patients suffering from chronic conditions. Owing to that, non-critical procedures such as elective surgeries were either canceled or postponed during the first and second quarters of 2020, which resulted in a significant decline in the total number of elective surgical procedures performed. As a result, the demand for biosurgery products witnessed a sharp decline in 2020. The second wave of COVID-19 further deprioritized elective surgical procedures. Governments across the globe have also issued limitations and bans on medical procedures and elective surgeries. With the current pandemic scenario, surgical procedures have witnessed a decline and are only expected to increase in the third quarter of 2021 in countries such as the US. Some countries in the EU have resumed surgical interventions, which has increased the demand for biosurgery products in the region.

Recent Developments

• November 2021, Triad Life Sciences, has put on the hard hat and is moving forward with plans to raise $40 million in an IPO through Canaccord Genuity.
• September 2021, Tissue Regenix, the regenerative the medical technology company, announced the launch of DermaPure Meshed and VNWTM, both line extensions to the company’s Biosurgery division, utilizing tissue Regenix’s patented decellularization Technology.
• April 2021, Aroa Biosurgery Limited, launched a new product named Myriad Morcells, which easily conforms to optimize contact with irregular wound beds.
• February 2020, Baxter announced 510 (k) clearance from US FDA for Peri-Strips Dry with Veritas Collagen Matrix product with Secure Grip. The product is a staple line reinforcement agent and is indicated for mitigating the bleeding during bariatric surgeries and other surgical procedures.
• February 2020, Integra Life Sciences Holdings Corp. launched Amnio Excel Plus Placental Allograft Membrane for use across soft tissue repair.
• October 2020, Orthofix Medical Inc., announced the launch of O-Genesis Graft Delivery System and AlloQuent Structural Allograft Q-Pack, a ready to use cervical and lumbar spacers for allograft procedures.

Biosurgery Market Report Coverage

• The report offers a comprehensive quantitative as well as qualitative analysis of the current global biosurgery market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
• A thorough analysis of aspects that boost and restrict the development of the market is provided.
• Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
• The forecasts in this report are made by examining the recent trends along with future biosurgery market potential from 2021 to 2031 in terms of revenue.
• Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global biosurgery industry.

Frequently Asked QuestionsQ. How big is the Biosurgery market?Ans. The global biosurgery market size was USD 12.4 billion in 2021 and is anticipated to reach USD 21.2 billion in 2031.Q. What is the Biosurgery market growth rate?Ans. The growth rate of the Biosurgery market is 5.5% from 2022 to 2031.Q. Which region holds a major market share for the Biosurgery market?Ans. North America holds a major market share of the Biosurgery market in 2021.Q. Which segment accounted for the largest Biosurgery market share?Ans. By end-user, the hospital’s segment accounted for the largest Biosurgery market shareQ. Who are the key players in the Biosurgery market?Ans. The global biosurgery market report includes players such as Johnson & Johnson (US), Baxter International Inc. (US), Medtronic Plc (Ireland), Becton, Dickinson & Co. (US), B. Braun Melsungen AG (Germany), Stryker Corp. (US), Integra Lifesciences Holdings Corp. (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Cyrolife Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), Smiths & Nephew Plc. (UK), Tissue Regenix Group Plc (UK), Betatech Medical (Turkey), Meril Lifesciences Pvt. Ltd. (India), RTI Surgicals (US), Samyang Holdings Corp. (South Korea), Aroa Biosurgery Ltd. (New Zealand), Meyer-Haake GmbH (Germany), Biom'Up (France), BioCer Entwicklungs-GmbH (Germany), and Hannox International Corp. (Taiwan) among others.Q. What are the factors driving the biosurgery market growth?Ans. The major factors driving the growth of the market are the increasing volume of surgeries and the growing prevalence of severe trauma injuries.Q. What are the key growth strategies of biosurgery market players?Ans. The key growth strategies of biosurgery market players are product launch and product approval.Q. Which region will provide more business opportunities for the biosurgery market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for biosurgery market during the forecast period

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.